Reliably Determining Reasonable Royalty Rates from Lump Sum Licenses - In Ecofactor, Inc. V. Google LLC, Appeal No. 23-1101, The Federal Circuit held that license agreements containing a lump sum payment “based on” a royalty...more
7/2/2024
/ Alice/Mayo ,
Appeals ,
Damages ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Google ,
Labeling ,
License Agreements ,
Lump Sum Payments ,
Motion to Dismiss ,
Patent Infringement ,
Patents ,
Pharmaceutical Patents ,
Royalties ,
Sports Gambling
Ranges for Interdependent and Interactive Components Can Be Tricky to Derive -
In Modernatx, Inc. v. Arbutus Biopharma Corporation, Appeal No. 20-2329, the Federal Circuit held that a presumption of obviousness based on...more
1/11/2022
/ AstraZeneca ,
Generic Drugs ,
Instrinsic Evidence ,
Intel ,
Inter Partes Review (IPR) Proceeding ,
Moderna Inc. ,
Mylan Pharmaceuticals ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs ,
Prior Art ,
Qualcomm
Venue and Pleading Infringement in Hatch-Waxman Litigation Turn on Location and Identity of ANDA Filer -
In Celgene Corp. v. Mylan Pharm. et al., Appeal No. 21-1154, the Federal Circuit held that in Hatch-Waxman...more
12/9/2021
/ Abbreviated New Drug Application (ANDA) ,
Apple ,
Article III ,
Biogen Idec ,
Dr. Reddy’s Labs. ,
Generic Drugs ,
Hatch-Waxman ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Mylan Pharmaceuticals ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs ,
Qualcomm ,
Standing ,
Written Descriptions
PTAB May Invalidate Claims on Reconsideration Based on Grounds Raised in the Institution Decision that Were Not Originally Instituted -
In AC Technologies S.A., V. Amazon.Com, Inc., Blizzard Entertainment, Inc., Appeal No....more
3/14/2019
/ Abbreviated New Drug Application (ANDA) ,
Amazon ,
Anticipation ,
Appeals ,
Article III ,
Due Process ,
Final Written Decisions ,
Generic Drugs ,
Hatch-Waxman ,
Hewlett-Packard ,
Inter Partes Review (IPR) Proceeding ,
Motivation to Combine ,
Mylan Pharmaceuticals ,
Obviousness ,
Orange Book ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Petition For Rehearing ,
Pharmaceutical Patents ,
Reaffirmation ,
Right To Appeal ,
Section 103 ,
Standing
Priority Claims Cannot Be Incorporated by Reference -
In Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Limited, Appeal Nos. 2016-2707 and 2016-2708, the Federal Circuit held that when a patent for a...more
6/25/2018
/ Abbreviated New Drug Application (ANDA) ,
Abuse of Discretion ,
Appeals ,
Claim Construction ,
Clear Error Standard ,
Consolidated Appeals ,
Diagnostic Method ,
Disclaimers ,
Discovery ,
Extrinsic Evidence ,
Generic Drugs ,
Incorporation by Reference ,
Injunctive Relief ,
Inter Partes Review (IPR) Proceeding ,
Jurisdiction ,
Patent Infringement ,
Patent Invalidity ,
Patent Terms ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Priority Patent Claims ,
Privity of Contract ,
Product of Nature Doctrine ,
Real Party in Interest ,
Scope of the Claim ,
Subsequent Litigation ,
Time-Barred Claims ,
Treatment Method Patents
Distribution Agreements Can Constitute Offers for Sale Under Section 102(b) -
In The Medicines Company v. Hospira, Inc., Appeal Nos. 2014-1469, 2014-1504, the Federal Circuit held that a distribution agreement qualified as...more
4/11/2018
/ Amended Complaints ,
Appeals ,
Broadest Reasonable Interpretation Standard ,
Claim Construction ,
Computer-Related Inventions ,
Direct Infringement ,
Federal Rule 12(b)(6) ,
Generic Drugs ,
Indefiniteness ,
Inter Partes Review (IPR) Proceeding ,
Motion to Dismiss ,
Obviousness ,
On-Sale Bar ,
Patent Invalidity ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Pleading Standards ,
Prior Art ,
Question of Fact ,
Question of Law ,
Remand ,
Reversal ,
Sales & Distribution Agreements ,
Section 101 ,
Standard of Review ,
Summary Judgment